We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




POCT Market Reaches USD 18 Billion in 2016

By LabMedica International staff writers
Posted on 10 Mar 2017
Sales of point of care (POC) diagnostic testing, both professional testing and self-testing, reached USD 18.4 billion in 2016, driven by emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices that aim to provide expedited diagnosis where the patient is seen or in the patient’s home. More...
These new technologies are allowing POC devices to generate quantitative lab-quality test results and transfer them automatically to an information system, a remote caregiver service for consultation or an electronic medical record.

These are the latest findings of Kalorama Information, an independent medical market research firm.

Over the past 10 years, POC test devices have contributed significantly to the growth of the overall diagnostics market. A large number of diagnostic manufacturers have focused on obtaining CLIA waiver status for their POC devices and CE Mark for POC or self-use. Additionally, more decentralized test venues are investing in non-waived rapid tests and instruments POC testing is expected to play an even more significant role in diagnosis and monitoring patient care.

Currently, molecular POC tests in physician office are available for respiratory infections and more. The market for POC molecular test devices will be driven by their ability to provide precise answers for time sensitive tests, such as sexually transmissible diseases and other infections.

However, with lab budgets across the world being cut for test send-outs, there is a lack of trained technologists to run molecular tests in their present configuration. The new pharma model will resolve this by tailoring therapy to the individual’s particular disease physiology, often determined by the results of a diagnostic test. As a result, more tests – molecular and immunoassays – are expected to come to market, with their adoption being based on performance data, contribution to patient outcome and cost/benefit analysis.

An aging population across the world will provide sufficient room for growth of the POC testing market in the developing as well as developed countries. The evolving POC testing market comprises large and small companies involved in development and/or marketing. The key companies are likely to maintain their leading position in the market through continued product innovation and strategic alliances and mergers.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.